Chief Executive Officer

Khurem Farooq

Khurem has over 20 years’ drug development and operational leadership experience in the international biotech industry, with expertise across in-licensing, commercialization and business development. He was co-founder and CEO of Aiolos Bio prior to its acquisition by GSK in 2024. Khurem also served as CEO of Gyroscope Therapeutics which was acquired by Novartis in 2021. Previously, he was Senior Vice President of the Immunology and Ophthalmology business unit at Genentech, a member of the Roche Group.

At Genentech, he led the commercialization and launch planning of a number of medicines in the Immunology and Ophthalmology area and helped drive several drug candidates through the pipeline as a member of the Late Stage Portfolio Committee. He was also actively involved in business development assessments for the organization.

Khurem began his career at Aventis, holding various roles in sales and marketing. Khurem holds an MBA from Aston University as well as a degree in Biological Sciences from Wolverhampton University.